BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Alphatec Holdings, Inc. Announces Completion of Public Offering of Common Stock and Full Exercise of Over Allotment Option


4/22/2010 8:51:47 AM

CARLSBAD, Calif., April 21, 2010 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced the closing of its previously announced public offering of 16,000,000 shares of its common stock, consisting of 8,000,000 primary shares sold by the Company and 8,000,000 shares sold by a selling shareholder, HealthpointCapital Partners, L.P. In addition, the Company announced that the underwriters exercised in full their over allotment option to purchase an additional 1,200,000 shares of common stock from each of the Company and the selling shareholder (2,400,000 shares in the aggregate). The price to the public in the offering was $5.00 per share. The Company's net proceeds from the sale of the 9,200,000 shares sold by it, including the shares sold pursuant to the over allotment option, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $42.5 million. The Company will not receive any proceeds from the sale of the shares by the selling shareholder.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->